Zacks Research Forecasts Lower Earnings for AngioDynamics

Key Points

• Zacks Research has revised its Q1 2026 EPS estimate for AngioDynamics down from ($0.13) to ($0.14) per share.
• The company reported a better-than-expected earnings result of ($0.03) EPS in its latest quarter, exceeding analysts' estimates by $0.09.
• Several firms have issued buy ratings for AngioDynamics, with price targets ranging from $16.00 to $24.00 per share.

AngioDynamics, Inc. (NASDAQ:ANGO - Free Report) - Equities research analysts at Zacks Research lowered their Q1 2026 EPS estimates for shares of AngioDynamics in a research report issued to clients and investors on Tuesday, August 5th. Zacks Research analyst R. Department now expects that the medical instruments supplier will post earnings of ($0.14) per share for the quarter, down from their prior estimate of ($0.13). The consensus estimate for AngioDynamics' current full-year earnings is ($0.37) per share. Zacks Research also issued estimates for AngioDynamics' Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.01 EPS, FY2026 earnings at ($0.30) EPS, Q1 2027 earnings at ($0.11) EPS, Q2 2027 earnings at ($0.03) EPS, Q4 2027 earnings at $0.00 EPS and FY2027 earnings at ($0.17) EPS.

AngioDynamics (NASDAQ:ANGO - Get Free Report) last issued its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.09. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The firm had revenue of $80.16 million during the quarter, compared to the consensus estimate of $74.26 million. During the same period in the prior year, the firm posted ($0.06) earnings per share. The company's quarterly revenue was up 13.0% compared to the same quarter last year.

A number of other brokerages also recently issued reports on ANGO. Canaccord Genuity Group boosted their price objective on shares of AngioDynamics from $15.00 to $17.00 and gave the company a "buy" rating in a research report on Wednesday, July 16th. HC Wainwright restated a "buy" rating and set a $16.00 target price on shares of AngioDynamics in a research note on Wednesday, July 16th. Finally, Lake Street Capital began coverage on shares of AngioDynamics in a research note on Wednesday, July 16th. They issued a "buy" rating and a $24.00 price target on the stock.

AngioDynamics Trading Down 1.2%

ANGO stock traded down $0.11 during midday trading on Thursday, hitting $8.41. The company's stock had a trading volume of 164,352 shares, compared to its average volume of 643,757. The company has a market cap of $341.53 million, a PE ratio of -10.13 and a beta of 0.67. AngioDynamics has a 12 month low of $5.83 and a 12 month high of $13.50. The firm's 50-day moving average is $9.64 and its 200-day moving average is $9.77.

Hedge Funds Weigh In On AngioDynamics

A number of institutional investors and hedge funds have recently bought and sold shares of the business. Integrated Quantitative Investments LLC acquired a new position in AngioDynamics during the second quarter worth about $241,000. Los Angeles Capital Management LLC acquired a new position in AngioDynamics in the 2nd quarter valued at about $139,000. Bastion Asset Management Inc. boosted its holdings in AngioDynamics by 46.5% in the 2nd quarter. Bastion Asset Management Inc. now owns 959,043 shares of the medical instruments supplier's stock valued at $9,810,000 after purchasing an additional 304,217 shares during the last quarter. Pier Capital LLC boosted its holdings in AngioDynamics by 40.5% in the 2nd quarter. Pier Capital LLC now owns 694,235 shares of the medical instruments supplier's stock valued at $6,887,000 after purchasing an additional 200,244 shares during the last quarter. Finally, Y Intercept Hong Kong Ltd boosted its holdings in AngioDynamics by 890.3% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 224,514 shares of the medical instruments supplier's stock valued at $2,227,000 after purchasing an additional 201,843 shares during the last quarter. 89.43% of the stock is currently owned by institutional investors and hedge funds.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.